Demographics for all patients who underwent leukapheresis at submission
| . | No bridging . | Bridging therapy . | P-value none vs RT . | P-value none vs CT . | P-value steroids vs none . | P-value steroids vs RT . | P-value steroids vs CT . | P-value CT vs RT . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Steroids . | RT . | CT . | CMT . | ||||||||
| N = 49 . | N = 35 . | N = 62 . | N = 213 . | N = 16 . | |||||||
| Age, y | 63.0 (58-68) | 58.0(51-65) | 57.0(49-66) | 60.0(51-68) | 63.0(47.5-66.5) | .0082 | .080 | .069 | .54 | .78 | .20 |
| Sex, N (%) | |||||||||||
| Male | 30 (61.2) | 21 (60.0) | 37 (59.7) | 134 (62.9) | 8 (50.0) | >.99 | .87 | >.99 | >.99 | .85 | .66 |
| Female | 19 (38.8) | 14 (40.0) | 25 (40.3) | 79 (37.1) | 8 (50.0) | ||||||
| Disease type, N (%) | |||||||||||
| De novo DLBCL | 31 (63.3) | 24 (68.6) | 40 (64.5) | 148 (69.5) | 9 (56.3) | .95 | .72 | .53 | .58 | .30 | .44 |
| PMBL | 3 (6.1) | 0 | 4 (6.5) | 11 (5.2) | 2 (12.5) | ||||||
| tFL | 12 (24.5) | 10 (28.6) | 16 (25.8) | 39 (18.3) | 4 (25.0) | ||||||
| t-Other | 3 (6.1) | 1 (2.9) | 2 (3.2) | 15 (7.0) | 1 (6.3) | ||||||
| DHL/THL, N (%) | |||||||||||
| No | 28 (75.7) | 24 (75.0) | 38 (69.1) | 128 (68.8) | 8 (61.5) | .84 | .78 | >.99 | .88 | .87 | .84 |
| Yes | 4 (10.8) | 3 (9.4) | 8 (14.5) | 23 (12.4) | 2 (15.4) | ||||||
| DE/TE | 5 (13.5) | 5 (15.6) | 9 (16.4) | 35 (18.8) | 3 (23.1) | ||||||
| Missing/unknown | 12 | 3 | 7 | 27 | 3 | ||||||
| Stage, N (%) | |||||||||||
| Stage 1-2 | 14 (30.4) | 9 (25.7) | 18 (29.5) | 33 (15.6) | 2 (13.3) | >.99 | .033 | .80 | .82 | .15 | .024 |
| Stage 3-4 | 32 (69.6) | 26 (74.3) | 43 (70.5) | 179 (84.4) | 13 (86.7) | ||||||
| Missing/unknown | 3 | 0 | 1 | 1 | 1 | ||||||
| ECOG, N (%) | |||||||||||
| 0 | 31 (63.3) | 18 (51.4) | 32 (51.6) | 80 (37.6) | 3 (18.8) | .25 | .001 | .37 | >.99 | .14 | .056 |
| 1 | 18 (36.7) | 17 (48.6) | 30 (48.4) | 133 (62.4) | 13 (81.3) | ||||||
| Bulk>7.5cm, N (%) | |||||||||||
| No | 39 (79.6) | 26 (74.3) | 41 (66.1) | 149 (70.0) | 8 (53.3) | .14 | .22 | .61 | .50 | .69 | .64 |
| Yes | 10 (20.4) | 9 (25.7) | 21 (33.9) | 64 (30.0) | 7 (46.7) | ||||||
| Missing/unknown | 0 | 0 | 0 | 0 | 1 | ||||||
| No. of extra nodal sites, N (%) | |||||||||||
| None | 29 (59.2) | 15 (44.1) | 25 (40.3) | 59 (27.7) | 4 (25.0) | .039 | <.001 | .083 | .90 | .19 | .041 |
| 1-2 | 19 (38.8) | 14 (41.2) | 33 (53.2) | 129 (60.6) | 9 (56.3) | ||||||
| 3+ | 1 (2.0) | 5 (14.7) | 4 (6.5) | 25 (11.7) | 3 (18.8) | ||||||
| Missing/unknown | 0 | 1 | 0 | 0 | 0 | ||||||
| LDH, N (%) | |||||||||||
| <ULN | 12 (25.0) | 10 (28.6) | 19 (33.3) | 40 (19.6) | 0 | .83 | .062 | .79 | .67 | .23 | .039 |
| >ULN | 29 (60.4) | 17 (48.6) | 26 (45.6) | 104 (51.0) | 10 (71.4) | ||||||
| >2ULN | 7 (14.6) | 8 (22.9) | 12 (21.1) | 60 (29.4) | 4 (28.6) | ||||||
| Missing/unknown | 1 | 0 | 5 | 9 | 2 | ||||||
| IPI, N (%) | |||||||||||
| 0-2 | 26 (60.5) | 20 (57.1) | 32 (56.1) | 93 (45.1) | 8 (57.1) | .69 | .093 | .82 | >.99 | .20 | .18 |
| 3+ | 17 (39.5) | 15 (42.9) | 25 (43.9) | 113 (54.9) | 6 (42.9) | ||||||
| Missing/unknown | 6 | 0 | 5 | 7 | 2 | ||||||
| Fit for SCT?, N (%) | |||||||||||
| No | 11 (22.4) | 7 (20.0) | 6 (9.7) | 43 (20.2) | 5 (31.3) | .11 | .70 | >.99 | .21 | >.99 | .061 |
| Yes | 38 (77.6) | 28 (80.0) | 56 (90.3) | 170 (79.8) | 11 (68.8) | ||||||
| HCT-CI score, N (%) | |||||||||||
| <3 | 47 (95.9) | 30 (85.7) | 59 (96.7) | 194 (91.9) | 13 (81.3) | >.99 | .54 | .12 | .22 | .22 | .26 |
| ≥3 | 2 (4.1) | 5 (14.3) | 2 (3.3) | 17 (8.1) | 3 (18.8) | ||||||
| Missing/unknown | 0 | 0 | 1 | 2 | 0 | ||||||
| Life expectancy of <3 mo if no response to bridging, N (%) | |||||||||||
| No | 42 (85.7) | 20 (58.8) | 42 (67.7) | 120 (56.3) | 11 (68.8) | .044 | <.001 | .009 | .50 | .85 | .14 |
| Yes | 7 (14.3) | 14 (41.2) | 20 (32.3) | 93 (43.7) | 5 (31.3) | ||||||
| Missing/unknown | 0 | 1 | 0 | 0 | 0 | ||||||
| >2 previous lines, N (%) | |||||||||||
| No | 29 (59.2) | 19 (54.3) | 43 (69.4) | 123 (57.7) | 12 (75.0) | .32 | .87 | .66 | .19 | .72 | .11 |
| Yes | 20 (40.8) | 16 (45.7) | 19 (30.6) | 90 (42.3) | 4 (25.0) | ||||||
| Previous transplant, N (%) | |||||||||||
| No | 41 (83.7) | 30 (85.7) | 51 (82.3) | 173 (81.2) | 13 (81.3) | .60 | .93 | >.99 | .36 | .70 | .69 |
| Auto | 7 (14.3) | 4 (11.4) | 11 (17.7) | 35 (16.4) | 3 (18.8) | ||||||
| Allo | 1 (2.0) | 1 (2.9) | 0 | 5 (2.3) | 0 | ||||||
| Refractory, N (%) | |||||||||||
| No | 24 (50.0) | 21 (60.0) | 34 (55.7) | 117 (57.6) | 9 (60.0) | .57 | .42 | .38 | .83 | .85 | .88 |
| Yes | 24 (50.0) | 14 (40.0) | 27 (44.3) | 86 (42.4) | 6 (40.0) | ||||||
| Missing/unknown | 1 | 0 | 1 | 10 | 1 | ||||||
| Response to last line, N (%) | |||||||||||
| CMR/PR | 18 (36.7) | 13 (37.1) | 15 (24.2) | 50 (23.5) | 5 (31.3) | .21 | .070 | >.99 | .24 | .096 | >.99 |
| SD/PD | 31 (63.3) | 22 (62.9) | 47 (75.8) | 163 (76.5) | 11 (68.8) | ||||||
| . | No bridging . | Bridging therapy . | P-value none vs RT . | P-value none vs CT . | P-value steroids vs none . | P-value steroids vs RT . | P-value steroids vs CT . | P-value CT vs RT . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Steroids . | RT . | CT . | CMT . | ||||||||
| N = 49 . | N = 35 . | N = 62 . | N = 213 . | N = 16 . | |||||||
| Age, y | 63.0 (58-68) | 58.0(51-65) | 57.0(49-66) | 60.0(51-68) | 63.0(47.5-66.5) | .0082 | .080 | .069 | .54 | .78 | .20 |
| Sex, N (%) | |||||||||||
| Male | 30 (61.2) | 21 (60.0) | 37 (59.7) | 134 (62.9) | 8 (50.0) | >.99 | .87 | >.99 | >.99 | .85 | .66 |
| Female | 19 (38.8) | 14 (40.0) | 25 (40.3) | 79 (37.1) | 8 (50.0) | ||||||
| Disease type, N (%) | |||||||||||
| De novo DLBCL | 31 (63.3) | 24 (68.6) | 40 (64.5) | 148 (69.5) | 9 (56.3) | .95 | .72 | .53 | .58 | .30 | .44 |
| PMBL | 3 (6.1) | 0 | 4 (6.5) | 11 (5.2) | 2 (12.5) | ||||||
| tFL | 12 (24.5) | 10 (28.6) | 16 (25.8) | 39 (18.3) | 4 (25.0) | ||||||
| t-Other | 3 (6.1) | 1 (2.9) | 2 (3.2) | 15 (7.0) | 1 (6.3) | ||||||
| DHL/THL, N (%) | |||||||||||
| No | 28 (75.7) | 24 (75.0) | 38 (69.1) | 128 (68.8) | 8 (61.5) | .84 | .78 | >.99 | .88 | .87 | .84 |
| Yes | 4 (10.8) | 3 (9.4) | 8 (14.5) | 23 (12.4) | 2 (15.4) | ||||||
| DE/TE | 5 (13.5) | 5 (15.6) | 9 (16.4) | 35 (18.8) | 3 (23.1) | ||||||
| Missing/unknown | 12 | 3 | 7 | 27 | 3 | ||||||
| Stage, N (%) | |||||||||||
| Stage 1-2 | 14 (30.4) | 9 (25.7) | 18 (29.5) | 33 (15.6) | 2 (13.3) | >.99 | .033 | .80 | .82 | .15 | .024 |
| Stage 3-4 | 32 (69.6) | 26 (74.3) | 43 (70.5) | 179 (84.4) | 13 (86.7) | ||||||
| Missing/unknown | 3 | 0 | 1 | 1 | 1 | ||||||
| ECOG, N (%) | |||||||||||
| 0 | 31 (63.3) | 18 (51.4) | 32 (51.6) | 80 (37.6) | 3 (18.8) | .25 | .001 | .37 | >.99 | .14 | .056 |
| 1 | 18 (36.7) | 17 (48.6) | 30 (48.4) | 133 (62.4) | 13 (81.3) | ||||||
| Bulk>7.5cm, N (%) | |||||||||||
| No | 39 (79.6) | 26 (74.3) | 41 (66.1) | 149 (70.0) | 8 (53.3) | .14 | .22 | .61 | .50 | .69 | .64 |
| Yes | 10 (20.4) | 9 (25.7) | 21 (33.9) | 64 (30.0) | 7 (46.7) | ||||||
| Missing/unknown | 0 | 0 | 0 | 0 | 1 | ||||||
| No. of extra nodal sites, N (%) | |||||||||||
| None | 29 (59.2) | 15 (44.1) | 25 (40.3) | 59 (27.7) | 4 (25.0) | .039 | <.001 | .083 | .90 | .19 | .041 |
| 1-2 | 19 (38.8) | 14 (41.2) | 33 (53.2) | 129 (60.6) | 9 (56.3) | ||||||
| 3+ | 1 (2.0) | 5 (14.7) | 4 (6.5) | 25 (11.7) | 3 (18.8) | ||||||
| Missing/unknown | 0 | 1 | 0 | 0 | 0 | ||||||
| LDH, N (%) | |||||||||||
| <ULN | 12 (25.0) | 10 (28.6) | 19 (33.3) | 40 (19.6) | 0 | .83 | .062 | .79 | .67 | .23 | .039 |
| >ULN | 29 (60.4) | 17 (48.6) | 26 (45.6) | 104 (51.0) | 10 (71.4) | ||||||
| >2ULN | 7 (14.6) | 8 (22.9) | 12 (21.1) | 60 (29.4) | 4 (28.6) | ||||||
| Missing/unknown | 1 | 0 | 5 | 9 | 2 | ||||||
| IPI, N (%) | |||||||||||
| 0-2 | 26 (60.5) | 20 (57.1) | 32 (56.1) | 93 (45.1) | 8 (57.1) | .69 | .093 | .82 | >.99 | .20 | .18 |
| 3+ | 17 (39.5) | 15 (42.9) | 25 (43.9) | 113 (54.9) | 6 (42.9) | ||||||
| Missing/unknown | 6 | 0 | 5 | 7 | 2 | ||||||
| Fit for SCT?, N (%) | |||||||||||
| No | 11 (22.4) | 7 (20.0) | 6 (9.7) | 43 (20.2) | 5 (31.3) | .11 | .70 | >.99 | .21 | >.99 | .061 |
| Yes | 38 (77.6) | 28 (80.0) | 56 (90.3) | 170 (79.8) | 11 (68.8) | ||||||
| HCT-CI score, N (%) | |||||||||||
| <3 | 47 (95.9) | 30 (85.7) | 59 (96.7) | 194 (91.9) | 13 (81.3) | >.99 | .54 | .12 | .22 | .22 | .26 |
| ≥3 | 2 (4.1) | 5 (14.3) | 2 (3.3) | 17 (8.1) | 3 (18.8) | ||||||
| Missing/unknown | 0 | 0 | 1 | 2 | 0 | ||||||
| Life expectancy of <3 mo if no response to bridging, N (%) | |||||||||||
| No | 42 (85.7) | 20 (58.8) | 42 (67.7) | 120 (56.3) | 11 (68.8) | .044 | <.001 | .009 | .50 | .85 | .14 |
| Yes | 7 (14.3) | 14 (41.2) | 20 (32.3) | 93 (43.7) | 5 (31.3) | ||||||
| Missing/unknown | 0 | 1 | 0 | 0 | 0 | ||||||
| >2 previous lines, N (%) | |||||||||||
| No | 29 (59.2) | 19 (54.3) | 43 (69.4) | 123 (57.7) | 12 (75.0) | .32 | .87 | .66 | .19 | .72 | .11 |
| Yes | 20 (40.8) | 16 (45.7) | 19 (30.6) | 90 (42.3) | 4 (25.0) | ||||||
| Previous transplant, N (%) | |||||||||||
| No | 41 (83.7) | 30 (85.7) | 51 (82.3) | 173 (81.2) | 13 (81.3) | .60 | .93 | >.99 | .36 | .70 | .69 |
| Auto | 7 (14.3) | 4 (11.4) | 11 (17.7) | 35 (16.4) | 3 (18.8) | ||||||
| Allo | 1 (2.0) | 1 (2.9) | 0 | 5 (2.3) | 0 | ||||||
| Refractory, N (%) | |||||||||||
| No | 24 (50.0) | 21 (60.0) | 34 (55.7) | 117 (57.6) | 9 (60.0) | .57 | .42 | .38 | .83 | .85 | .88 |
| Yes | 24 (50.0) | 14 (40.0) | 27 (44.3) | 86 (42.4) | 6 (40.0) | ||||||
| Missing/unknown | 1 | 0 | 1 | 10 | 1 | ||||||
| Response to last line, N (%) | |||||||||||
| CMR/PR | 18 (36.7) | 13 (37.1) | 15 (24.2) | 50 (23.5) | 5 (31.3) | .21 | .070 | >.99 | .24 | .096 | >.99 |
| SD/PD | 31 (63.3) | 22 (62.9) | 47 (75.8) | 163 (76.5) | 11 (68.8) | ||||||
Compares RT/CT/CMT. P-values are χ2 or Fisher exact test (discreate variables) or Kruskal-Wallis (continuous).
CMR, complete metabolic response; DHL, double hit lymphoma; DE, double expressor; HCT-CI, Hematopoietic Cell Transplantation-specific Comorbidity Index; PMBL, primary mediastinal B-cell lymphoma; SCT, stem cell transplant; SD, stable disease; tFL, transformed follicular lymphoma; THL, triple hit lymphoma; TE, triple expressor; ULN, upper limit of normal.